| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new research published in the peer-reviewed journal Pharmaceuticals. The research article, titled "Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro," highlights the promising protective properties of the Company's clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.
Senior author Dr. Richard K. Porter, Associate Professor at Trinity College Dublin, Ireland, stated, "This groundbreaking research demonstrated ART27.13's ability to protect against muscle degeneration associated with colon and lung cancers. Based on this in vitro data, ART27.13 has the potential to protect against muscle wasting, which could result in increased quality of life and may ultimately impact life expectancy for patients suffering from cancer."
Artelo is currently evaluating ART27.13, a dual CB1/CB2 receptor agonist, in the Cancer Appetite Recovery Study (CAReS) Phase 2a clinical trial to determine its effect on lean body mass, weight gain, activity levels, and improvement of anorexia in cancer patients. The purpose of this new research was to establish whether ART27.13 may additionally impact muscle degradation, a common debilitating effect of cancer and its treatment. Not only did the research show that ART27.13 protects against muscle wasting in the in vitro model, but also shows that the activity was mediated by the CB2 receptor.
Steven D. Reich, M.D., Chief Medical Officer of Artelo, commented "This in vitro data supports our confidence in ART27.13's potential as a supportive care therapy for cancer patients as it may not only increase appetite, but also prevent muscle wasting. We are actively enrolling patients in the trial and look forward to reporting on our continued progress."
Professor Richard K. Porter authored the research paper in collaboration with Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, Dr. Andrew Yates, Senior Vice President and Chief Scientific Officer of Artelo, together with Dr. John Noone, Dr. Mary F. Rooney and Dr. Marilena Karavyraki based at the Trinity Biomedical Science Institute (TBSI), Trinity College Dublin, Ireland.
About ART27.13
ART27.13 is a highly potent, peripherally restricted synthetic, dual G-Protein-Coupled Receptor agonist believed to target the cannabinoid receptors CB1 and CB2, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca plc, ART27.13 has been evaluated in five Phase 1 clinical studies including over 200 subjects where it has demonstrated a statistically significant and dose-dependent increase in body weight in healthy subjects. Importantly, the changes in body weight were not associated with fluid retention and the distribution of the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Artelo is advancing ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss, where the current annual global market is estimated to be valued in excess of $2 billion.
About CAReS
The Cancer Appetite Recovery Study (CAReS) is a Phase 1b/2a randomized, placebo-controlled trial of the Company's lead clinical program, ART27.13, in patients with cancer anorexia and weight loss. Anorexia, or the lack or loss of appetite, may result from the cancer and/or its treatment with radiation or chemotherapy. It is common for patients with cancer to lose weight. Anorexia and the resulting weight loss can affect a patient's health, often weakening their immune system and causing discomfort and dehydration. A weight loss of more than 5% can predict a poor outcome for cancer patients and a lower response to chemotherapy. The Phase 1b portion of the CAReS study is designed to determine the most effective and safest dose of ART27.13 for dosing in the Phase 2a stage. The Phase 2a portion of the CAReS study is designed to determine estimates of activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia. (ISRCTN registry: https://www.isrctn.com/ISRCTN15607817)
Posted In: ARTL
